JP2020512820A - 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 - Google Patents

補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 Download PDF

Info

Publication number
JP2020512820A
JP2020512820A JP2019554816A JP2019554816A JP2020512820A JP 2020512820 A JP2020512820 A JP 2020512820A JP 2019554816 A JP2019554816 A JP 2019554816A JP 2019554816 A JP2019554816 A JP 2019554816A JP 2020512820 A JP2020512820 A JP 2020512820A
Authority
JP
Japan
Prior art keywords
human igm
seq
constant region
modified human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019554816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512820A5 (enExample
Inventor
ラメッシュ バリガ
ラメッシュ バリガ
ディーン エング
ディーン エング
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド, アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2020512820A publication Critical patent/JP2020512820A/ja
Publication of JP2020512820A5 publication Critical patent/JP2020512820A5/ja
Priority to JP2023062508A priority Critical patent/JP2023085503A/ja
Priority to JP2024175523A priority patent/JP2024177479A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019554816A 2017-04-07 2018-04-06 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 Withdrawn JP2020512820A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023062508A JP2023085503A (ja) 2017-04-07 2023-04-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
JP2024175523A JP2024177479A (ja) 2017-04-07 2024-10-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483087P 2017-04-07 2017-04-07
US62/483,087 2017-04-07
PCT/US2018/026474 WO2018187702A2 (en) 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062508A Division JP2023085503A (ja) 2017-04-07 2023-04-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域

Publications (2)

Publication Number Publication Date
JP2020512820A true JP2020512820A (ja) 2020-04-30
JP2020512820A5 JP2020512820A5 (enExample) 2021-10-07

Family

ID=63713537

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554816A Withdrawn JP2020512820A (ja) 2017-04-07 2018-04-06 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
JP2023062508A Pending JP2023085503A (ja) 2017-04-07 2023-04-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
JP2024175523A Pending JP2024177479A (ja) 2017-04-07 2024-10-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023062508A Pending JP2023085503A (ja) 2017-04-07 2023-04-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域
JP2024175523A Pending JP2024177479A (ja) 2017-04-07 2024-10-07 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域

Country Status (11)

Country Link
US (2) US11401337B2 (enExample)
EP (1) EP3607091A4 (enExample)
JP (3) JP2020512820A (enExample)
KR (1) KR102696143B1 (enExample)
CN (1) CN110536900B (enExample)
AU (1) AU2018248336B2 (enExample)
CA (1) CA3055790A1 (enExample)
IL (1) IL268901B2 (enExample)
MX (1) MX2019011986A (enExample)
SG (1) SG11201908051RA (enExample)
WO (1) WO2018187702A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
KR20240135877A (ko) 2015-03-04 2024-09-12 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
US10604559B2 (en) 2015-03-25 2020-03-31 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
HK1252791A1 (zh) 2015-09-30 2019-06-06 Igm Biosciences, Inc. 具有经修饰的j链的结合分子
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
EP3607091A4 (en) * 2017-04-07 2021-01-20 IGM Biosciences, Inc. MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
SG11202103720XA (en) * 2018-10-23 2021-05-28 Igm Biosciences Inc MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
JP2022544405A (ja) * 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
WO2021055765A2 (en) * 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
AU2021260928A1 (en) 2020-04-22 2022-10-27 Igm Biosciences, Inc. PD-1 agonist multimeric binding molecules
JP2025506341A (ja) * 2022-02-03 2025-03-11 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ３８結合分子及びその使用
CA3245061A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T-CELL RECEIVER MULTIMERS AND THEIR USES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04221321A (ja) * 1990-04-03 1992-08-11 Miles Inc 熱処理されたＩｇＭ抗体製剤
JP2013510164A (ja) * 2009-11-04 2013-03-21 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2015129651A1 (ja) * 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DK1707627T3 (da) 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
EP1814913B1 (en) 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antibody induced cell membrane wounding
WO2013049254A1 (en) 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
JP6335796B2 (ja) 2012-02-08 2018-06-06 アイジーエム バイオサイエンシズ インク．Ｉｇｍ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｃｄｉｍ結合タンパク質及びその使用
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
US9416496B2 (en) * 2013-10-16 2016-08-16 Georgia-Pacific Consumer Products Lp Method for reducing the bulk and increasing the density of a tissue product
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
KR20240135877A (ko) 2015-03-04 2024-09-12 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
US10604559B2 (en) 2015-03-25 2020-03-31 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
HK1252791A1 (zh) 2015-09-30 2019-06-06 Igm Biosciences, Inc. 具有经修饰的j链的结合分子
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
WO2018017889A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
AU2017298483A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric OX40 binding molecules and uses thereof
CA3030634A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
WO2018017763A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
EP3607091A4 (en) * 2017-04-07 2021-01-20 IGM Biosciences, Inc. MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
SG11202103720XA (en) 2018-10-23 2021-05-28 Igm Biosciences Inc MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04221321A (ja) * 1990-04-03 1992-08-11 Miles Inc 熱処理されたＩｇＭ抗体製剤
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
JP2013510164A (ja) * 2009-11-04 2013-03-21 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
WO2015129651A1 (ja) * 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. MOL. BIOL., vol. 221, JPN6022010139, 1991, pages 1345 - 1366, ISSN: 0004729084 *
PROC. NATL. ACAD. SCI. USA, vol. 83, JPN6022010138, 1986, pages 7678 - 7682, ISSN: 0004729083 *

Also Published As

Publication number Publication date
IL268901B1 (en) 2025-07-01
EP3607091A2 (en) 2020-02-12
WO2018187702A2 (en) 2018-10-11
EP3607091A4 (en) 2021-01-20
IL268901A (en) 2019-10-31
SG11201908051RA (en) 2019-09-27
IL268901B2 (en) 2025-11-01
JP2024177479A (ja) 2024-12-19
US20210147567A1 (en) 2021-05-20
AU2018248336B2 (en) 2024-10-03
AU2018248336A1 (en) 2019-09-26
CA3055790A1 (en) 2018-10-11
KR102696143B1 (ko) 2024-08-21
CN110536900A (zh) 2019-12-03
KR20190137821A (ko) 2019-12-11
US20220340676A1 (en) 2022-10-27
CN110536900B (zh) 2024-06-11
US11401337B2 (en) 2022-08-02
JP2023085503A (ja) 2023-06-20
MX2019011986A (es) 2019-11-07

Similar Documents

Publication Publication Date Title
US20220340676A1 (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
JP7499813B2 (ja) 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
JP6793655B2 (ja) Ｃｄ２０結合分子およびその使用方法
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
JP7585305B2 (ja) 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
US20220306760A1 (en) Igm glycovariants
JP2025506341A (ja) 抗ｃｄ３８結合分子及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191004

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230407

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230413

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230417

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251015